Clark Estates Inc. NY Has $21.88 Million Stock Position in IQVIA Holdings Inc. $IQV

Clark Estates Inc. NY trimmed its position in IQVIA Holdings Inc. (NYSE:IQV) by 25.8% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 115,200 shares of the medical research company’s stock after selling 40,000 shares during the period. IQVIA comprises approximately 5.0% of Clark Estates Inc. NY’s holdings, making the stock its 2nd largest holding. Clark Estates Inc. NY owned about 0.07% of IQVIA worth $21,881,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Alliancebernstein L.P. raised its holdings in IQVIA by 0.6% during the 2nd quarter. Alliancebernstein L.P. now owns 3,555,929 shares of the medical research company’s stock worth $560,379,000 after purchasing an additional 19,573 shares during the last quarter. Artisan Partners Limited Partnership acquired a new stake in shares of IQVIA during the 2nd quarter worth approximately $515,772,000. JPMorgan Chase & Co. raised its stake in shares of IQVIA by 22.8% during the second quarter. JPMorgan Chase & Co. now owns 3,126,171 shares of the medical research company’s stock worth $492,659,000 after buying an additional 581,157 shares during the last quarter. Nordea Investment Management AB lifted its holdings in IQVIA by 12.3% in the third quarter. Nordea Investment Management AB now owns 2,314,219 shares of the medical research company’s stock valued at $421,257,000 after buying an additional 253,759 shares during the period. Finally, Cantillon Capital Management LLC boosted its stake in IQVIA by 27.3% in the third quarter. Cantillon Capital Management LLC now owns 1,926,934 shares of the medical research company’s stock valued at $366,002,000 after acquiring an additional 413,256 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Trading Down 2.2%

NYSE:IQV opened at $165.63 on Monday. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.75. The business’s 50-day simple moving average is $217.61 and its 200-day simple moving average is $208.66. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $247.04. The stock has a market capitalization of $28.11 billion, a PE ratio of 21.07, a price-to-earnings-growth ratio of 1.60 and a beta of 1.37.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, beating analysts’ consensus estimates of $3.40 by $0.02. The firm had revenue of $4.36 billion for the quarter, compared to analyst estimates of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The business’s revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

IQV has been the subject of several recent research reports. Robert W. Baird set a $258.00 target price on shares of IQVIA and gave the company an “outperform” rating in a research report on Wednesday, October 29th. Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a research note on Saturday. Weiss Ratings restated a “hold (c)” rating on shares of IQVIA in a research report on Thursday, January 22nd. Citigroup cut their price target on shares of IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a research report on Friday, February 6th. Finally, BMO Capital Markets set a $250.00 price objective on shares of IQVIA in a research note on Friday, February 6th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and an average target price of $235.20.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.